Kezar Life Sciences, Inc.
NASDAQ:KZR
6.64 (USD) • At close December 27, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Kezar Life Sciences, Inc. |
Symbool | KZR |
Munteenheid | USD |
Prijs | 6.64 |
Beurswaarde | 48,446,901 |
Dividendpercentage | 0% |
52-weken bereik | 5.2 - 11.4 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. John Franklin Fowler |
Website | https://www.kezarlifesciences.com |
An error occurred while fetching data.
Over Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)